DNA-Based Population Screening for Adults.
1/5 보강
AbstractPopulation screening is a long-established tool for effectively identifying disease risk when existing approaches are inadequate for optimizing care.
APA
Saylor KW, Rasmussen SA, Murray MF (2026). DNA-Based Population Screening for Adults.. NEJM evidence, 5(2), EVIDra2500218. https://doi.org/10.1056/EVIDra2500218
MLA
Saylor KW, et al.. "DNA-Based Population Screening for Adults.." NEJM evidence, vol. 5, no. 2, 2026, pp. EVIDra2500218.
PMID
41590991 ↗
Abstract 한글 요약
AbstractPopulation screening is a long-established tool for effectively identifying disease risk when existing approaches are inadequate for optimizing care. DNA-based population screening (DNAPS) in adult populations has the power to identify individuals at an increased genetic risk of cancer, heart disease, and other health conditions, thus allowing for evidence-based interventions to reduce associated morbidity and mortality. One example of the type of risk identified in such screening is - and -associated cancer risk, where current risk-identification strategies have been shown to miss greater than 70% of at-risk individuals. Since the first DNA-based screening pilot in adults was initiated in 2008, a growing number of other large-scale projects carrying out DNAPS in adults have followed, and, in aggregate, these projects are engaging millions of people around the world. There are features of DNAPS that make this population screening approach distinct from other population health screens, such as the scale of the datasets that will be created and stored for each participant. This review focuses on an examination of DNAPS in the context of other population health screens, the state of the evidence for this screening approach, and gaps to be addressed to optimize implementation of this population screening approach.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Comprehensive analysis of androgen receptor splice variant target gene expression in prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.